BioNTech SE is 4.6x more valuable than CRISPR Therapeutics AG by market capitalization ($21.79 B vs $4.77 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CRSP | BNTX |
|---|---|---|
| Market cap | $4.77 B | $21.79 B |
| US-listed rank | #1422 | #587 |
| Revenue (latest FY) | $3.51M | - |
| Net income (latest FY) | -$581.60M | - |
| Net margin | -16569.8% | - |
| SEC filings | 837 | 548 |
BioNTech SE is 4.6x more valuable than CRISPR Therapeutics AG by market capitalization ($21.79 B vs $4.77 B).
Full pages: CRISPR Therapeutics AG and BioNTech SE, or browse the full rankings.